ICD 9 Codes

PGx medication risk prediction model

This algorithm predicts those who are going to be exposed to warfarin, simvastatin, or clopidogrel as three medications that have known pharmacogenomic influences.  This algorithm was used to select individuals for the Vanderbilt PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment) program, which prospectively tests individuals at risk of needing medications whose efficacy is effected by genetic variants.  

 

For more information on PREDICT, see http://mydruggenome.org.

Owner Phenotyping Groups: 
Final

PhEMA BPH (Benign Prostatic Hyperplasia) cases

This is PhEMA (Phenotype Execution Modeling Architecture, projectphema.org)'s implementation of the following BPH (Benign Prostatic Hyperplasia) case algorithm from the following BPH case and control algorithm on PheKB:

https://phekb.org/phenotype/benign-prostatic-hyperplasia-bph

Artifacts for this phenotype, inc. an HQMF representation, a KNIME workflow that can run against an i2b2 instance, and a snapshot of the PhAT graphical representation, are posted on GitHub:

Final

Red Blood Cell Indices

Laboratory results for ESR and RBC indices (hemoglobin, MCV, MCH, RDW… etc) should be extracted from the Laboratory databases. For Mayo, from January 1994 till October 2009, ESR and RBC test results were populated for our 3336 participants. All samples were collected on an outpatient basis. Samples collected during an inpatient hospitalization (admit date ≤ collection date ≤ discharge date) should be excluded unless this sample was the only one available for a patient.

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Sleep Apnea Phenotype

  • The computable phenotype for the Sleep Apnea Patient Centered Outcomes Network uses existing and well established ICD codes for different types of sleep apnea including 327.23 (adult and pediatric obstructive sleep apnea), 780.51 (insomnia with sleep apnea), 780.53 (hypersomnia with sleep apnea), and 780.57 (unspecified sleep apnea).
Final

Statins and MACE

Phenotype Description:  Patients on statins for primary prevention who develop an AMI or 1st AMI. 

Below are algorithms used to identify AMI and 1st AMI cohort at BioVU. If you have questions regarding any of the information presented on this page, you may contact either:

Wei-Qi Wei at wei-qi.wei@vanderbilt.edu

Joshua Denny at josh.denny@vanderbilt.edu

 

             

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Pages